Cargando…

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)

Detalles Bibliográficos
Autores principales:	Rüfer, Axel, Angermann, Hubert, Benz, Rudolf, Bonadies, Nicolas, Calderoni, Antonello, Cantoni, Nathan, Efthymiou, Anna, Escher, Robert, Favre, Geneviève, Friess, Dorothea, Gschwend, Andreas, Himmelmann, Andreas, Holbro, Andreas, Keller, Peter, Kouroupi, Eirini, Lehmann, Thomas, Pedarnig, Nikolaus, Rigamonti, Véronique, Samii, Kaveh, Schmidt, Adrian, Schäfer, Hans-Peter, Sperb, Roland, Stüssi, Georg, Winkler, Annette, Zenhäusern, Reinhard, Goede, Jeroen S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208896/ https://www.ncbi.nlm.nih.gov/pubmed/35747588 http://dx.doi.org/10.1097/HS9.0000000000000741

Ejemplares similares

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
por: Krönke, Jan, et al.
Publicado: (2015)

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
por: Giagounidis, Aristoteles A. N., et al.
Publicado: (2006)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome
por: Alshaban, Ahmed, et al.
Publicado: (2018)

Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy
por: Vaccarino, Antonella, et al.
Publicado: (2016)

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
por: Kuendgen, A, et al.
Publicado: (2013)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Practical Strategies for Management of Lenalidomide-Associated Cytopenias in Myelodysplastic Syndromes With del(5q)
por: Kurtin, Sandra E., et al.
Publicado: (2017)

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2020)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
por: Follo, Matilde Y., et al.
Publicado: (2019)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series
por: Stein, Anna, et al.
Publicado: (2022)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
por: Mei, Y, et al.
Publicado: (2018)

PP2A: The Achilles Heal in MDS with 5q Deletion
por: Sallman, David A., et al.
Publicado: (2014)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity
por: Hong, Junshik, et al.
Publicado: (2021)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert!
por: Al-Jafar, Hassan A., et al.
Publicado: (2012)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone
por: Washington, Nyomi R, et al.
Publicado: (2021)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion
por: Stalmann, Ursula S. A., et al.
Publicado: (2022)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor–TRAF6 signaling
por: Varney, Melinda E., et al.
Publicado: (2015)

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
por: Park, Isaac, et al.
Publicado: (2021)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m5m6g713ng7mk20m0a17i97r4j